You are viewing a preview of...

CLEC9A mAb Vaccine Delivery Platform - Cancer and Infectious Diseases

An immunisation strategy using the anti-Clec9A antibody that produces superior results to alternative methods

Technology Overview

Clec9A is selectively expressed by cDC1, the dendritic cell population with cross-presentation ability. Researchers at Monash University have designed a novel immunisation strategy utilizing anti-Clec9A antibody conjugated with antigen (), which elicits very potent antigen-specific T cell and B cell immune responses. Compared to a competing technology targeting DEC205, this approach induces superior (25-fold better) antibody responses.

Further Details:

  • The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments, Immunity (2012) 36 (4): 646–657
  • Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype, J Immunol (2011) 87(2):842-50
  • The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement, Blood (2008) 112 (8):

Log in or create a free account to continue reading